GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives $4.14 Consensus PT from Analysts

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) have received a consensus recommendation of “Hold” from the thirteen research firms that are currently covering the company, MarketBeat reports. Three research analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $4.1364.

A number of research firms have weighed in on GDRX. Weiss Ratings upgraded GoodRx from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, August 7th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $4.00 price objective on shares of GoodRx in a research report on Friday, August 7th. UBS Group increased their price objective on GoodRx from $2.50 to $3.75 and gave the company a “neutral” rating in a report on Thursday, August 13th. Citigroup raised their target price on GoodRx from $4.00 to $5.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Finally, Wall Street Zen upgraded GoodRx from a “hold” rating to a “buy” rating in a research note on Saturday.

Institutional Trading of GoodRx

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GDRX. Lazard Asset Management LLC increased its position in GoodRx by 43.6% during the 2nd quarter. Lazard Asset Management LLC now owns 17,142 shares of the company’s stock worth $85,000 after purchasing an additional 5,201 shares during the period. Brevan Howard Capital Management LP raised its stake in shares of GoodRx by 7.7% during the 3rd quarter. Brevan Howard Capital Management LP now owns 95,483 shares of the company’s stock worth $404,000 after buying an additional 6,842 shares in the last quarter. Hirtle Callaghan & Co LLC lifted its holdings in shares of GoodRx by 60.3% in the 4th quarter. Hirtle Callaghan & Co LLC now owns 18,261 shares of the company’s stock valued at $49,000 after buying an additional 6,869 shares during the period. Tower Research Capital LLC TRC lifted its holdings in shares of GoodRx by 202.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company’s stock valued at $56,000 after buying an additional 7,580 shares during the period. Finally, Quarry LP purchased a new stake in shares of GoodRx in the third quarter valued at approximately $33,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

GoodRx Trading Down 1.9%

Shares of NASDAQ:GDRX opened at $3.65 on Friday. GoodRx has a 52 week low of $1.77 and a 52 week high of $5.81. The company’s 50 day moving average is $3.07 and its two-hundred day moving average is $2.61. The company has a market cap of $1.25 billion, a PE ratio of 91.27, a P/E/G ratio of 1.77 and a beta of 1.60. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.74.

GoodRx (NASDAQ:GDRX) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.08 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.08. The business had revenue of $200.41 million during the quarter, compared to analysts’ expectations of $193.23 million. GoodRx had a net margin of 2.07% and a return on equity of 7.22%. The company’s revenue for the quarter was down 1.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.09 EPS. Equities analysts predict that GoodRx will post 0.16 earnings per share for the current fiscal year.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.